CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $255,455 | -25.4% | 5,628 | -7.7% | 0.00% | 0.0% |
| Q2 2023 | $342,286 | +26.0% | 6,097 | +1.5% | 0.00% | 0.0% |
| Q1 2023 | $271,606 | +6.4% | 6,005 | -4.4% | 0.00% | +50.0% |
| Q4 2022 | $255,323 | -99.9% | 6,281 | -53.4% | 0.00% | -60.0% |
| Q3 2022 | $440,440,000 | +106030.1% | 13,476 | +97.1% | 0.01% | +25.0% |
| Q2 2022 | $415,000 | +22.1% | 6,837 | +26.4% | 0.00% | 0.0% |
| Q1 2022 | $340,000 | +4.3% | 5,410 | +25.6% | 0.00% | +33.3% |
| Q4 2021 | $326,000 | -76.6% | 4,308 | -65.5% | 0.00% | -78.6% |
| Q3 2021 | $1,396,000 | -29.3% | 12,472 | +2.2% | 0.01% | -36.4% |
| Q2 2021 | $1,975,000 | +170.9% | 12,200 | +104.0% | 0.02% | +144.4% |
| Q1 2021 | $729,000 | -58.0% | 5,981 | -44.3% | 0.01% | -55.0% |
| Q4 2020 | $1,735,000 | – | 10,737 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |